Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Hindalco 172.00 0.79
Tata Stl 522.85 0.41
Ong Corp 427.75 2.31
Bhel 229.20 1.29
Tata Mot 521.60 1.70
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Wockhardt Limited
Wockhardt Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:532300NSE:WOCKPHARMABloomberg:WPL@INReuters:WCKH.BO
Market Lot: 1Face Value: 5ISIN Demat: INE049B01025
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
12-AUG-14 Wockhardt, one of the leading pharmaceutical and biotechnology company, today reported a fall of 93.83% in consolidated net profit to Rs 199.5 million for the quarter ended June 30, 2014 as compared to Rs 3,233.1 million in the same period last year. 04-JUN-14 Wockhardt shares slipped on Wednesday after media reports said that the US regulator has identified deficiencies in quality, hygiene and personnel training standards at Wockha...   More..
Business Profile Future Plans
CEO Talk
Wockhardt Ltd is exploring possibilities of co-licensing WCK-771 and WCK-919. The company intends to focus essentially on the anti-infective therapeutic segment as it accounts for 12 per cent of the total pharma market and is the third largest therapeutic segment.   Habil Khorakiwala
One To One
Recent news
Latest News
Wockhardt consolidated Q1 profit plunges 93.8%  -IRIS 12-Aug-14
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Mar-2014 (12)31-Mar-2013 (12)31-Mar-2012 (12)
Net sales 18052.7024711.8025604.00
Other Income2787.40653.40201.20
Total Income20840.1025365.2025805.20
Cost of goods sold17392.6018998.2017265.30
OPBDIT3447.506367.008539.90
PAT1986.106227.001840.00
Gross Block---
Equity capital548.80547.90547.20
EPS (Rs.)18.1056.8816.81
DPS (Rs.)---
BV (Rs.)---
P/E range (x)18.60 - 114.3610.51 - 38.0814.95 - 36.99
Debt / Equity (x)---
Operating margin (% of OI)16.525.133.1
Net margin (% of OI) 9.524.5 7.1
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Wockhardt Towers
Bandra Kurla Complex
Bandra (East)
Mumbai
Maharashtra-400 051
PHONE
(022) 2653 4444
FAX
(022) 2653 4242
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer